Mineral and bone disorders in children with chronic kidney disease

Area of Science:

• Pediatric Nephrology
• Mineral and Bone Disorders
• Chronic Kidney Disease (CKD) Management

Background:

• Children with chronic kidney disease (CKD) require lifelong management, making bone and mineral homeostasis critical for skeletal, growth, and cardiovascular health.
• Assessing bone disease in pediatric CKD is challenging due to unreliable biochemical markers and limited imaging techniques.
• Emerging factors like fibroblast growth factor 23 (FGF23) require further investigation in pediatric CKD.

Purpose of the Study:

• To highlight the importance of optimal bone and mineral homeostasis in children with CKD.
• To discuss current challenges in assessing bone disease in this population.
• To review current and emerging therapeutic strategies for mineral and bone disorders in pediatric CKD.

Main Methods:

• Review of current literature on mineral and bone disorders in pediatric CKD.
• Discussion of diagnostic limitations and controversies.
• Evaluation of existing and novel therapeutic interventions, including vitamin D supplementation, phosphate binders, and cinacalcet.

Main Results:

• Ergocalciferol or cholecalciferol supplementation and calcium-free phosphate binders are recommended despite limited evidence.
• Cinacalcet shows promise but requires more pediatric data, especially regarding its effects on growth and development.
• Ongoing randomized controlled trials are investigating cinacalcet's pharmacokinetics and pharmacodynamics in infants.

Conclusions:

• Effective management of bone and mineral homeostasis is crucial for long-term health in pediatric CKD patients.
• Further research and robust clinical trials are needed to establish optimal treatment targets and evaluate new therapies like cinacalcet.
• Addressing diagnostic and therapeutic challenges is essential for improving outcomes in children with CKD-related mineral and bone disease.